Skip to Main Content

Pathology Research Faculty

Pathology Research Faculty - Primary

  • Demetrios Braddock was born in Tennessee, educated at the University of Chicago, trained at the NIH in Anatomic Pathology and Biophysical Chemistry, and came to Yale in 2004. He practices Hematopathology and leads a laboratory that studies the ENPP enzymes – a family of extracellular enzymes that create small molecules in the extracellular environment that regulate organismal homeostasis in processes such as hemostasis, bone mineralization, and vascular development. We are especially interested in a rare disease of lethal vascular calcifications called 'Generalized Arterial Calcification of Infancy' (GACI) associated with ENPP1 deficiency, and designed and validated an enzyme therapy that was curative in a mouse model of GACI. We are now moving this therapy into patients in collaboration with a company we founded (Inozyme Pharma). We have also identified a form of early onset osteoporosis associated with ENPP1 deficiency, and are investigating the role of ENPP1 in low bone mass and increased tissue calcification, a medical condition called 'Paradoxical Mineralization' which occurs in the general medical population in conditions such as aging and chronic kidney disease.

  • José Costa, MD, FACP, is Professor Emeritus of Pathology at Yale University School of Medicine and Professeur Honoraire at the University of Lausanne Switzerland. Dr. Costa is an internationally renowned leader in the field of diagnostics of cancer and pathogenesis of tumor formation. Having contributed to the transition from opinion-based medicine to evidence-based diagnosis, he is now making use of novel tools to practice integrative systems pathology, an approach that strives to enable a personalized, predictive and precise diagnosis.

    Prior his transition to Emeritus status April 1, 2018, at the Yale School of Medicine, Dr Costa served in several positions of leadership that include: Chief of the Anatomical Pathology Branch at the Clinical Center, NIH Bethesda Md (1980-83); Director of the Institute of Pathology, University of Lausanne, Lausanne, Switzerland (1983-1993); President of the Board of Directors of the Centre Pluridisciplinaire d’Oncologie, Lausanne Switzerland (1985-1992); Director of Anatomical Pathology Yale New Haven Hospital (1993-2007); and Deputy Director of the Yale Comprehensive Cancer Center (1995-2007). He is a sought-after advisor to several academic, research, and health organizations, and has served or currently serves as board member or advisor to several institutions including the ISREC (Swiss Cancer Research Institut); the Ludwig Institut Branch in Lausanne; the Deutsche Krebs Forschung Zenter (Heidelberg); the Institut of Molecular Pathology at Porto (Portugal); The Catalan Institut of Oncology [ICO] Barcelona, Spain; the Centro Nacional de Investigacion en Oncologia [CNIO] Madrid,Spain, the Instituto Carlos III, Madrid, Spain, the Center for Virtual Tumor Modeling (Harvard); the NIH Consensus Panels and the NCI’s EDRN in Bethesda, MD, USA.

    Throughout his career, Dr. Costa has integrated advances in basic understanding of cancer to the clinical area of diagnosis, prognosis, and early detection. He has contributed over 170 original publications to the technical literature, and is among a small group of investigators using evolutionary and ecological theory to predict tumor behavior. His laboratory investigates the micro-evolutionary dynamics involved in tumor formation and tumor progression using both experimental and theoretical modeling at the systems level. This work has identified novel and promising ways to detect early cancer and ways to follow the changes in tumors under therapy. Dr. Costa is co-inventor of two novel diagnostic technologies and has served in the oversight board of Yale’s Office of Cooperative Research. He has also been involved in the crafting of public-private joint ventures in Switzerland (IP-AMS Labs [1999]), the early launching of Curagen Corporation (New Haven, CT [1996]), the founding of Aureon Biosciences (Yonkers, NY [2001]), VCN (Barcelona, Spain [2005]), and PetaOmics (San Marcos, TX [2014]).

    The contributions of Dr. Costa have been recognized by several awards, including a Special Achievement Award from NIH, election as a Fellow to the American Association for the Advancement of Science (2003), the Gold Medal of the International Academy of Pathology. and the Trueta Medal from the Catalan government for contributions to public health.

    A firm believer in the dynamics coming from multi-disciplinarity and cooperation, Dr. Costa continues to create an environment that will transform health care and set the standards for the 21st century. He is particularly interested in exploring synergies between academia, private industry, and governmental programs.

  • Karin Finberg received her B.S., M.D., and Ph.D. degrees from Yale. Her Ph.D. dissertation with Dr. Richard Lifton in the Department of Genetics focused on the genetic basis of an autosomal recessive disorder of systemic pH homeostasis, distal renal tubular acidosis with sensorineural deafness. After graduating from Yale, Karin completed residency training in Clinical Pathology at Massachusetts General Hospital and clinical fellowship training in the Harvard Medical School Molecular Genetic Pathology Training Program based at Brigham and Women’s Hospital. She then completed postdoctoral research training in the laboratory of Dr. Nancy Andrews, first at Children’s Hospital Boston and later at Duke University Medical Center, where she employed genetic study of patients with an inherited form of iron deficiency anemia to shed insight into mechanisms of systemic iron regulation. In her research laboratory at Yale, Karin continues to investigate mechanisms of iron balance through genetic study of patients with iron-related phenotypes and through characterization of genetically targeted mouse models. She also contributes to patient care as a molecular genetic pathologist in the Molecular Diagnostics Unit of the Department of Pathology.

  • Pallavi Gopal is a graduate of the Medical Scientist Training Program at the University of Pennsylvania, Perelman School of Medicine in Philadelphia. Her Ph.D. thesis work in Neuroscience with Dr. Jeffrey Golden focused on understanding the cellular and molecular mechanisms that guide neuronal migration during forebrain development. After earning her M.D., Pallavi completed postgraduate clinical training in Anatomic Pathology and Neuropathology at the Hospital of the University of Pennsylvania. She did her postdoctoral research training with Dr. Erika Holzbaur at the University of Pennsylvania. Dr. Gopal is a recipient of the NINDS Clinical Scientist Research Career Development Award. She joined the Pathology Department at Yale School of Medicine in January 2018.

  • My major interests are in diagnostic and experimental lung pathology. As the lead thoracic pathologist at Yale since 2004, I have experience in diagnosing and classifying the full range of histopathology of lung disease.

    I entered the MD-PhD program at Yale School of Medicine in 1979. My PhD with Donal Murphy described a novel antigenic structure within the murine MHC. Upon graduation I trained in Anatomic Pathology under the supervision of Dr. Juan Rosai and simultaneously completed a post-doctoral fellowship with Richard Flavell, chair of the section of immunobiology, with a focus on T cell tolerance. Lung specific pathology training mentors included Drs. G. J. Walker Smith, Darryl Carter and Raymond Yesner. I inherited from Dr. Smith a portion of the collection of Drs. Averill Leibow and Charles Carrington, two of the founders of modern surgical pathology of the lung.

    For many years, I worked on various murine models of inflammatory lung disease, ran an NIH funded morphology core for the Yale pulmonary section and ran a laboratory at West Haven VA looking at murine models of pulmonary fibrosis. I now still consult on various experimental models of lung disease and work with collaborators analyzing human fibrotic and neoplastic disease.

    I am heavily involved in medical school curriculum development as Director of Medical Studies for Pathology, am on the curriculum committee and am Co-Director of one of the new master courses for the new (starting 2015) pre-clinical curriculum for YSM.

    I have been Director of Anatomic Pathology at West Haven VA since 1994. 

  • Dr. Hudnall is an AP/CP board certified hematopathologist with a special interest in lymphoproliferative disorders and the role of chronic inflammation and tumor-infiltrating lymphocytes and monocytes in tumor progression. Dr. Hudnall is also interested in the role of infectious agents in lymphoproliferative disorders, with a special interest in herpes viruses.

  • Won Jae Huh completed his medical education at the Seoul National University in South Korea. Then he pursued Ph.D. training in Developmental Biology at Washington University in St. Louis. His Ph.D. thesis work with Dr. Jason Mills focused on the transcriptional regulation of gastric chief cell differentiation. Won Jae completed his residency training in Anatomic Pathology at Montefiore Medical Center/Albert Einstein College of Medicine, followed by fellowship in Gastrointestinal and Liver Pathology at Vanderbilt University Medical Center. He did his postdoctoral research training on EGFR and Notch signaling crosstalk in gastric premalignant conditions with Dr. Robert Coffey at Vanderbilt University Medical Center. Won Jae is a recipient of the NIDDK Clinical Scientist Career Development Award. He was an assistant professor at Vanderbilt University Medical Center prior to joining the Department of Pathology at Yale School of Medicine in 2021.

  • Dr. Hui is Professor in the Department of Pathology and Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine. He received combined anatomic and clinical pathology residency training at Yale-New Haven Hospital in 2000, followed by Oncological Pathology Fellowship training at MSKCC. He joined the pathology faculty at Yale in 2001. Dr. Hui is a board certified surgical pathologist with clinical specialty areas including gynecologic pathology and molecular diagnostics. Currently, he is Director of Gynecologic Pathology Service and Clinical director of the Molecular Diagnostics Laboratory.

    Dr. Hui oversees a dynamic, high volume gynecologic pathology program with emphasis on precision diagnosis of gynecological tumors, oncological biomarker identification and clinical applications, and understanding the pathogenesis of various gynecological cancers. Dr. Hui has particular expertise in the diagnosis and translational research of gestational trophoblastic disease (GTD). He serves on the editorial boards of International Journal of Gynecological Pathology, Modern Pathology, Human Pathology and Journal of Clinical Pathology. He has authored over 240 publications and written four gynecological pathology textbooks including "Cytology and Surgical Pathology of Gynecologic Neoplasms", "Gestational Trophoblastic Disease: Diagnostic and Molecular Genetic Pathology", "Atlas of Intraoperative Frozen Section Diagnosis in Gynecologic Pathology", and "Practical Gynecologic Pathology". Dr. Hui was an editorial board member of the 4th (2014) and the 5th (2020) editions of the WHO Blue Book of tumor classifications of female reproductive organs. Dr. Hui serves on the Board of Directors of the International Society of Gynecological Pathologists (ISGyP).

  • Michael Kashgarian is professor emeritus of and senior research scientist in pathology. He received his medical degree from Yale School of Medicine in 1958, completed his residency in pathology at the Yale-New Haven Medical Center in 1963, and completed a fellowship in laboratory medicine at Yale-New Haven Hospital in 1964. While on the Yale faculty he established a diagnostic renal pathology and electron microscopy laboratory that bears his name. He was also a pioneer in understanding the process of organ rejection. Although Kashgarian has retired, he continues to be active in the diagnosis of renal and cardiac biopsies.

  • Samuel G. Katz graduated with a combined B.S./M.S. from Yale University in 1995. He then pursued dual M.D., Ph.D. training in the Health Sciences & Technology (HST) program jointly administered by MIT and Harvard. His Ph.D. thesis with Stuart H. Orkin focused on the transcriptional regulation of hematopoiesis. Sam then completed a residency in pathology and fellowship in hematopathology at Brigham and Women’s Hospital. He performed his post-doctoral studies on apoptosis with Loren D. Walensky at the Dana Farber Cancer Institute. As an Associate Professor of Pathology at Yale University, Dr. Katz manages a laboratory concentrating on both intrinsic mechanisms of cell death and ways to reprogram immunocytes to mediate the extrinsic program of cell death, as well as contributes to patient care as an active hematopathologist.

  • Dr. Steven Kleinstein is a computational immunologist with a combination of big data analysis and immunology domain expertise. His research interests include both developing new computational methods and applying these methods to study human immune responses. Dr. Kleinstein received a B.A.S. in Computer Science from the University of Pennsylvania and a Ph.D. in Computer Science from Princeton University. He is currently Professor of Pathology (with a secondary appointment in Immunobiology) at the Yale School of Medicine, and a member of the Interdepartmental Program in Computational Biology and Bioinformatics (CBB), and the Human and Translational Immunology Program. 

    Specific areas of research focus include:

    • High-throughput single-cell B cell receptor (BCR) repertoire profiling (AIRR-seq, Rep-seq, scRNA-seq+VDJ)
    • Multi-omic immune signatures of human infection and vaccination responses

  • I have been working in the broad fields of bioinformatics, machine learning, applied mathematics and dynamics of quantum fields.  My current research interests relate to development of spectral methods and unsupervised & supervised deep learning approaches for analyzing high dimensional genomics, transcriptomics, epigenomics and proteomics data from various modalities.  I apply these methods in the context of cancer, immunobiology,  brain and phylogeny studies with the aim of revealing cell specific regulatory networks and characterizing biomarkers.

  • Dr. Kyriakides completed a PhD at Washington State University in 1993. He did a postdoctoral fellowship at the University of Washington and has expertise in the areas of extracellular matrix, inflammation, angiogenesis and arteriogenesis in relation to tissue repair. The Kyriakides lab is investigating the regulation and function of matricellular proteins that modulate cell-extracellular matrix interactions. Our overall goal is to create novel engineering strategies based on biological observations to enhance tissue repair. Dr. Kyriakides is Director of Graduate Studies for the Experimental Pathology PhD program. He also serves as a mentor for students from the School of Engineering and Applied Science.

  • Morgan Levine is a ladder-rank Assistant Professor in the Department of Pathology at the Yale School of Medicine and a member of both the Yale Combined Program in Computational Biology and Bioinformatics, and the Yale Center for Research on Aging. The overall goals of her lab are to: 

    1) Quantify the biological aging process that underlies the etiology of diseases ranging from cancer to Alzheimer's.

    2) Discover mechanisms of aging that can be targeted to delay or prevent disease and extend life expectancy.

    Her work relies on an interdisciplinary approach, integrating theories and methods from bioinformatics, cellular biology, and biostatistics to track trajectories aging cells, tissues, and organisms take through time. As PI or co-Investigator on multiple NIH-, Foundation-, and University-funded projects, she has extensive experience using systems-level and machine learning approaches to track epigenetic, transcriptomic, and proteomic changes with aging and incorporate this information to develop biomarkers of aging and disease risk.

  • Zachary Levine is currently an Assistant Professor of Pathology and of Molecular Biophysics & Biochemistry at the Yale School of Medicine and the Graduate School at Yale University. While trained in computational biophysics with special emphasis in protein folding, his interests have recently expanded into solution biophysics measurements of soluble amyloid oligomers. Many of his projects combine atomistic molecular dynamics (MD) simulations with single-molecule fluorescence techniques (smFRET, FCS, and anisotropy) in order to deduce the physical and thermodynamic determinants of age-related diseases.

    In particular, his lab seeks to understand protein aggregation diseases from a biophysical perspective. Many of these conditions involve a toxic accumulation of amyloid proteins and plaques over the lifecourse, leading to degenerative dysfunction and death. By combining molecular models of protein folding and aggregation with solution biophysics techniques, the Levine lab structurally and functionally characterizes amyloid oligomers that are distinctly pathological in order to mitigate degenerative diseases and age-related processes.

  • I am a graduate of Yale College (BA 1957), Oxford University (D.Phil.1961)
    and the Yale School of Medicine (MD, 1963). I trained in anatomical
    pathology at Washington University (1963-65), spent a post-doctoral year at
    Rockefeller University with George Palade, and served in the USPHS at the
    NIH from1966 to 1972.

    I was recruited to Yale by Lewis Thomas in 1972, and a
    year later was named the Anthony N. Brady Professor of pathology and chair
    of the department and Pathologist-in-Chief of the Yale New Haven Hospital.
    In 1991 I became the Director of the Boyer Center for Molecular Medicine. I
    am a member of the National Academy of Sciences and the Institute of

  • Wang Min, Ph.D., received his B.S. degree in Microbiology from Wuhan University in 1984, his M.S degree in Cell Biology at Shanghai Institute of Cell Biology, Chinese Academy of Sciences, in 1989, and his Ph.D degree in Genetics at University of Wales, Swansea, U.K., in 1993. He then performed 4-year post-doctoral training in vascular biology and immunology at the Department of Pathology, Yale School of Medicine. He became a Senior Scientist and Project Leader at GeneMedicine, Inc., in 1997 and then an Assistant Professor at University of Rochester, NY, in 1999. In 2003, he was recruited back to Department of Pathology and Vascular Biology Program at Yale School of Medicine, where he was promoted to Professor with Tenure in 2013. Dr. Min is a member of NAVBO, AHA, Yale Stem Cell Center and Yale Cancer Center. The goal in Dr. Min's lab is to dissect the signaling pathways, establish mouse models, and define the fundamental mechanisms involved in vascular development, remodeling, and repair related to human diseases such as vascular malformation, ischemia, and stroke. Dr. Min's lab has extensively employed biochemical, cell biological, and mouse genetic approaches to define the critical molecules mediating vascular development, remodeling, and repair. Dr. Min serves on the editorial board of Arteriosclerosis, Thrombosis, and Vascular Biology and Frontiers in Physiology. Dr. Min has been the recipient of many awards, including the Irvine H. Page Young Investigator Research Award, the AHA Established Investigator Award, the JACC Parmley Award, and CT Stem Cell EIA Award.